Status:
RECRUITING
Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions:
Thymus Neoplasms
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the efficiency and toxicity of adjuvant hypofractionation radiotherapy for thymic epithelial tumours after complete resection.
Detailed Description
Adjuvant Radiotherapy(Postoperative radiotherapy) is proposed in stage II and III thymic carcinoma，stage III thymoma，stage IIB B2/B3 thymomas. Hypofractionation Radiotherapy is used in this study. Th...
Eligibility Criteria
Inclusion
- Thymoma and Thymic carcinoma confirmed by histology or cytology
- R0 resection (complete resection)
- stage II and III thymic carcinoma，stage III thymoma，stage IIB B2/B3 thymomas.
- Karnofsky performance status(KPS) 80, 90 or 100.
- Having sufficient Pulmonary function, renal function and liver function. Neutrophile granulocyte count\>1.5×109 /L, platelet count\>80×109 /L, hemoglobin ≥10g/dL.
Exclusion
- Prior thoracic radiotherapy.
- Uncontrolled Comorbidities.
- Pregnant or nursing mother.
- Pneumonia
Key Trial Info
Start Date :
November 11 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2040
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06189183
Start Date
November 11 2023
End Date
December 31 2040
Last Update
February 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Beijing, Beijing Municipality, China, 100021